{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:44:38Z","timestamp":1786164278008,"version":"build-2736575974"},"reference-count":50,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016047","name":"Science Fund of the Republic of Serbia","doi-asserted-by":"crossref","award":["6777"],"award-info":[{"award-number":["6777"]}],"id":[{"id":"10.13039\/501100016047","id-type":"DOI","asserted-by":"crossref"}]},{"award":["6777"],"award-info":[{"award-number":["6777"]}],"id":[{"id":"https:\/\/ror.org\/02r531a15","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: The safety profile of adalimumab in inflammatory bowel disease (IBD) has been established in clinical trials, but post-marketing surveillance remains important for detecting rare and late-onset adverse events (AEs). This study aimed to evaluate long-term safety and temporal dynamics of AEs in an IBD cohort treated with adalimumab, and to identify potential safety signals using the FDA Adverse Event Reporting System (FAERS). Methods: This retrospective single-center study included patients with IBD treated with adalimumab. Demographic, clinical, and treatment-related data, including AEs and newly identified extraintestinal manifestations (EIMs), were collected. Time-to-event (TTE) analyses were used to assess AEs temporal patterns and covariates associated with onset. FAERS disproportionality analysis was performed for cohort-identified AEs and EIMs. Results: A total of 217 patients with 591.29 patient-years (PYs) of exposure (up to 9.62 years) were included. AE incidence was 106.6\/100 PY. Time to first AE was described using the Kaplan\u2013Meier method, and additionally the Weibull distribution, with an estimated median time of 11.4 months (95% CI: 9.7\u201313.5). The most frequent AEs were infections (32.30\/100 PY), hepatic events (9.98\/100 PY), and cutaneous manifestations (8.46\/100 PY), characterized by TTE analysis. Serious outcomes, including malignancies and demyelinating events, were rare. Several unlisted MedDRA preferred terms, including infectious, cutaneous, vascular, proliferative, and musculoskeletal events, emerged as FAERS signals. Conclusions: This study provides long-term real-world evidence supporting the established safety profile of adalimumab in IBD. First AEs occurred throughout treatment exposure with lower hazard over time. Isolated FAERS signals, including vascular occlusive events, may warrant further investigation and continued pharmacovigilance.<\/jats:p>","DOI":"10.3390\/ph19081239","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:03:27Z","timestamp":1786021407000},"page":"1239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adalimumab Safety in Inflammatory Bowel Disease: A Clinical Cohort Study with Time-to-Event Analysis and FAERS Signal Assessment"],"prefix":"10.3390","volume":"19","author":[{"given":"Bojana","family":"Mila\u0161inovi\u0107","sequence":"first","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-5704","authenticated-orcid":false,"given":"Sr\u0111an","family":"Markovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Zvezdara University Medical Center, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vezmar Kova\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-812X","authenticated-orcid":false,"given":"Petar","family":"Svorcan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Zvezdara University Medical Center, 11000 Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5088-5976","authenticated-orcid":false,"given":"Branislava","family":"Miljkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9676-5785","authenticated-orcid":false,"given":"Katarina","family":"Vu\u010di\u0107evi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Borowitz, S.M. (2022). The epidemiology of inflammatory bowel disease: Clues to pathogenesis?. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.1103713"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Barbieri, M.A., Viola, A., Cicala, G., Spina, E., and Fries, W. (2022). Effectiveness and safety profiles of biological therapies in inflammatory bowel disease: Real life data from an active pharmacovigilance project. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123280"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1053\/gast.2000.18160","article-title":"Tumor necrosis factor: Biology and therapeutic inhibitors","volume":"119","author":"Papadakis","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1136\/gut.34.12.1705","article-title":"Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease","volume":"34","author":"Murch","year":"1993","journal-title":"Gut"},{"key":"ref_5","first-page":"355","article-title":"Adalimumab in Crohn\u2019s disease","volume":"1","author":"Vermeire","year":"2007","journal-title":"Biologics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ibd.20956","article-title":"Adalimumab safety in global clinical trials of patients with Crohn\u2019s disease","volume":"15","author":"Colombel","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_7","unstructured":"(2026, February 25). Humira FDA Approval History. Available online: https:\/\/www.drugs.com\/history\/humira.html."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: The CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: Results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/ajg.2014.242","article-title":"Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3","volume":"109","author":"Colombel","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","article-title":"Long-term safety of adalimumab in 29,967 adult patients from global clinical trials across multiple indications: An updated analysis","volume":"37","author":"Burmester","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"765","DOI":"10.5114\/aoms.2013.38670","article-title":"Tumor necrosis factor-\u03b1 antibodies (infliximab, adalimumab and certolizumab) in Crohn\u2019s disease: Systematic review and meta-analysis","volume":"9","author":"Kawalec","year":"2013","journal-title":"Arch. Med. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/17474124.2.2.163","article-title":"Efficacy and safety of adalimumab for the treatment of Crohn\u2019s disease in adults","volume":"2","author":"Colombel","year":"2008","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/apt.14420","article-title":"Long-term safety of adalimumab in clinical trials in adult patients with Crohn\u2019s disease or ulcerative colitis","volume":"47","author":"Colombel","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: Meta-analysis of placebo-controlled trials","volume":"6","author":"Deltenre","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: Meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_23","first-page":"1424","article-title":"Patients included in clinical trials of biological drugs for inflammatory bowel disease do not represent the real-world population","volume":"121","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41395-018-0098-4","article-title":"Lymphoma risk and overall safety profile of adalimumab in patients with Crohn\u2019s disease with up to 6 years of follow-up in the Pyramid registry","volume":"113","author":"Reinisch","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1590\/s0004-2803.201700000-43","article-title":"Safety profile of anti-TNF therapy in Crohn\u2019s disease management: A Brazilian single-center direct retrospective comparison between infliximab and adalimumab","volume":"54","author":"Bau","year":"2017","journal-title":"Arq. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/ecco-jcc\/jjw060","article-title":"Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn\u2019s disease","volume":"10","author":"Ogata","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5217\/ir.2020.00033","article-title":"Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: Results from a large-scale, prospective, multicenter, observational study","volume":"19","author":"Ogata","year":"2021","journal-title":"Intest. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5217\/ir.2020.00025","article-title":"Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn\u2019s disease: 3-year results from a real-world study","volume":"19","author":"Hisamatsu","year":"2021","journal-title":"Intest. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2020.1786681","article-title":"Safety profiles of biologic agents for inflammatory bowel diseases: A prospective pharmacovigilance study in Southern Italy","volume":"36","author":"Roberti","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tallarico, M., Palleria, C., Ruffolo, L., Spagnuolo, R., Naturale, M.D., De Francesco, A.E., De Sarro, C., Romeo, R., Citraro, R., and Doldo, P. (2022). Biologics for inflammatory bowel disease in clinical practice: A Calabria (Southern Italy) prospective pharmacovigilance study. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112449"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14740338.2019.1630063","article-title":"Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi\u2019s) used in treatment of autoimmune diseases","volume":"18","author":"Chen","year":"2019","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_32","unstructured":"(2025, December 25). FDA\u2019s Adverse Event Reporting System (FAERS), Available online: https:\/\/www.fda.gov\/drugs\/surveillance\/fdas-adverse-event-reporting-system-faers."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cutroneo, P.M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., and Moretti, U. (2024). Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul., 3.","DOI":"10.3389\/fdsfr.2023.1323057"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14740338.2016.1145653","article-title":"A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn\u2019s disease","volume":"15","author":"Papamichael","year":"2016","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_35","unstructured":"U.S. Food and Drug Administration (2026, January 22). Adalimumab Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125057s425lbl.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.3748\/wjg.v23.i22.4102","article-title":"Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study","volume":"23","author":"Koller","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lopetuso, L.R., Mocci, G., Marzo, M., D\u2019Aversa, F., Rapaccini, G.L., Guidi, L., Armuzzi, A., Gasbarrini, A., and Papa, A. (2018). Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-\u03b1 on the liver. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082199"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/14740338.2015.976610","article-title":"Safety considerations when using anti-TNF\u03b1 therapy to treat Crohn\u2019s disease","volume":"14","author":"Pagnini","year":"2015","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4291\/wjgp.v6.i3.62","article-title":"Iron deficiency anemia in inflammatory bowel disease","volume":"6","author":"Kaitha","year":"2015","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12245-026-01235-9","article-title":"Celiac trunk thrombosis and splenic infarction in a patient with ankylosing spondylitis under adalimumab: A case report","volume":"19","author":"Grundmann","year":"2026","journal-title":"Int. J. Emerg. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Song, L., Yang, N., Xing, X., Zhao, Y., and Di, J. (2025). Thrombotic adverse events associated with TNF-alpha blockers: A real-world pharmacovigilance analysis of the FAERS database. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1512806"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1874312901206010315","article-title":"Anti-tumor necrosis factor-\u03b1 induced systemic lupus erythematosus","volume":"6","author":"Almoallim","year":"2012","journal-title":"Open Rheumatol. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.4081\/reumatismo.2024.1658","article-title":"Systemic lupus erythematosus induced by anti-tumor necrosis factor \u03b1 therapy in inflammatory rheumatic diseases: A case series","volume":"76","author":"Oliveira","year":"2024","journal-title":"Reumatismo"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.dld.2021.02.006","article-title":"Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort","volume":"53","author":"Xiao","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Shehab, M., Almajdi, A., Abdullah, I., and Alrashed, F. (2025). Safety and effectiveness of multi-switch between adalimumab originator and biosimilars: A multicenter (SUSTAIN) study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14248819"},{"key":"ref_46","unstructured":"U.S. Food and Drug Administration (2012). Guidance for Industry and Investigators, Safety Reporting Requirements for INDs and BA\/BE Studies."},{"key":"ref_47","unstructured":"(2026, February 14). OpenVigil 2.1. OpenVigil\u2014A Pharmacovigilance Data Analysis Tool. Available online: https:\/\/openvigil.sourceforge.net."},{"key":"ref_48","unstructured":"Beal, S.L., Sheiner, L.B., Boeckmann, A.J., and Bauer, R.J. (2022). NONMEM User\u2019s Guides (1989\u20132022), Icon Development Solutions."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1038\/psp.2013.18","article-title":"A time to event tutorial for pharmacometricians","volume":"2","author":"Holford","year":"2013","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.12793\/tcp.2022.30.e8","article-title":"A simple time-to-event model with NONMEM featuring right-censoring","volume":"30","author":"Tran","year":"2022","journal-title":"Transl. Clin. Pharmacol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:31:50Z","timestamp":1786163510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ph19081239"],"URL":"https:\/\/doi.org\/10.3390\/ph19081239","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}